Revolution Medicines announced positive clinical updates for daraxonrasib in treating metastatic pancreatic ductal adenocarcinoma. Long-term follow-up data in second-line patients showed promising activity and durability. Initial results in first-line patients were highly encouraging, supporting the start of a Phase 3 trial later this year. The company plans to evaluate daraxonrasib monotherapy and a combination with chemotherapy. These findings highlight the potential of daraxonrasib to become a new standard of care for pancreatic cancer patients. Revolution Medicines will host a webcast today to discuss these updates. Pancreatic cancer is a deadly disease with a high mortality rate, and new treatment options are urgently needed.

Read more at GlobeNewswire: Revolution Medicines Shares New Clinical Results Supporting